Researchers reported an antibody that targets influenza neuraminidase (NA) with broad neutralizing activity across diverse H5N1 strains. The study—described in press materials—characterizes cross‑clade potency and suggests NA‑focused biologics could complement HA‑directed vaccines and antivirals for pandemic preparedness. Neuraminidase is an enzyme involved in viral release; targeting it with broadly neutralizing antibodies offers an orthogonal route to block transmission and disease. The work may inform next‑generation influenza countermeasures and candidate therapeutic antibodies for zoonotic avian strains.